Test Price
550 AED✅ Home Collection Available
INI-1 Immunohistochemistry Test in UAE | 550 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – sample is collected via biopsy in a hospital setting; mobile home phlebotomy is disabled for safety.
Clinical Guidance: Telephonic Post‑Test Clinical Guidance for confident result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The INI-1 (SMARCB1) immunohistochemistry test detects loss of the INI‑1 protein in tumor tissue, a critical biomarker for atypical teratoid/rhabdoid tumors, epithelioid sarcomas, and other aggressive cancers. Using a clinically validated monoclonal antibody on formalin‑fixed paraffin‑embedded (FFPE) blocks or fresh formalin‑fixed tissue, this DHA‑compliant protocol delivers definitive results within 5–7 working days.
| Feature | Our Test (INI-1 IHC) | Closest Alternative (Generic IHC Panel) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity; INI‑1‑specific antibody (SMARCB1) | Variable; may use non‑specific markers |
| Methodology | Standardised IHC with DAB detection, ISO‑certified | Routine IHC without mandatory INI‑1 validation |
| Turnaround Time | 5‑7 working days (block/tissue) | Often >10 days; may require send‑out |
Physician Insight & Safety Protocols
“I understand that a cancer‑related test can feel overwhelming. The INI‑1 result must always be correlated with your full histopathology report and clinical symptoms. My team and I are here to answer your questions and guide the next steps with compassion and precision.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA License: 61713011
⚠️ Advisory: Medication Warning
Do not discontinue any prescribed medication without consulting your doctor. This test is a diagnostic aid and does not replace ongoing oncological management.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with severe, uncontrolled bleeding disorders may require supervised biopsy; notify our team in advance.
- ER Red Flags After Procedure: Sudden, severe pain at the biopsy site, fever above 38.5°C, or active bleeding that does not stop with gentle pressure — seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is the INI-1 immunohistochemistry test used for?
The INI-1 immunohistochemistry accurately identifies loss of the SMARCB1/INI-1 protein, aiding in the diagnosis of aggressive pediatric and adult cancers. It is most commonly performed on tissue from suspected atypical teratoid/rhabdoid tumors (AT/RT), epithelioid sarcomas, and poorly differentiated neoplasms where loss of INI‑1 is a defining molecular feature.
2. How is the sample collected and what preparation is required?
A tumor tissue sample is obtained through a biopsy, preserved in 10% formalin or as a formalin‑fixed paraffin‑embedded (FFPE) block, and sent at room temperature along with the histopathology report and clinical history. No special fasting or medication changes are needed; simply provide a copy of your existing pathology report and the biopsy site details.
3. What does a positive or negative INI‑1 result mean for my treatment?
A positive result (retained INI‑1 expression) does not rule out malignancy but helps refine the diagnosis, while a negative (lost) result strongly supports specific cancer types like AT/RT or epithelioid sarcoma. The finding guides precision therapy decisions and must be integrated with other molecular markers by your oncologist—never interpreted in isolation.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your clinical data and tissue samples are handled under strict confidentiality protocols aligned with Dubai Healthcare City regulations and DHA licensing requirements.
Clinical & Logistical Metadata
| Test Name | INI-1 (SMARCB1) Immunohistochemistry |
| Price (AED) | 550 |
| Turnaround Time | 5–7 working days (archival tissue) |
| Sample Type / Matrix | FFPE tissue block or fresh formalin-fixed tissue |
| Methodology Used | Immunohistochemistry (IHC) with DAB detection, ISO 9001:2015 |
| ICD-10-CM Code | C49.9 (Malignant neoplasm of connective and soft tissue, unspecified) |
| LOINC Code | 78777-6 (SMARCB1 gene expression in Tissue) |
| DHA Facility License & Laboratory Address | 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians